Fractyl Health (GUTS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Aug, 2026Executive summary
Special Meeting scheduled for September 24, 2026, will be held virtually to increase accessibility and reduce costs.
Only holders of record as of August 21, 2026, are entitled to vote on the matters presented.
The main item for consideration is a reverse stock split proposal to maintain Nasdaq listing compliance.
Voting matters and shareholder proposals
Stockholders are asked to approve amendments allowing a reverse stock split at a ratio between 1-for-5 and 1-for-15, at the Board's discretion.
The reverse stock split aims to increase the per-share trading price to meet Nasdaq's $1.00 minimum bid price requirement.
Approval requires a majority of votes cast; abstentions have no effect.
No other proposals or business are currently anticipated for the meeting.
Shareholder rights and capital structure
The reverse stock split will reduce outstanding shares but not authorized shares, increasing the number of shares available for future issuance.
All stockholders will be affected uniformly, with no material change to percentage ownership or voting power.
No fractional shares will be issued; cash will be paid in lieu of fractions.
The split could have anti-takeover effects by increasing unissued authorized shares.
Latest events from Fractyl Health
- A scalable, high-margin procedure addresses the urgent post-GLP-1 weight maintenance gap.GUTS
Status update - Revita offers a scalable, cost-effective solution for post-GLP-1 weight maintenance with rapid path to profitability.GUTS
Corporate presentation - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.GUTS
Proxy filing - Revita nears pivotal data for post-GLP-1 weight maintenance as Rejuva enters clinical trials.GUTS
Canaccord Genuity's 46th Annual Growth Conference - Revita maintained up to 84% of GLP-1 weight loss; net loss narrowed, but liquidity risks persist.GUTS
Q2 2026 - Revita enabled up to 84% weight loss retention at one year post-GLP-1, with strong safety data.GUTS
Study result - Innovative device and gene therapy programs target durable weight maintenance in obesity and diabetes.GUTS
Chardan's 8th Annual Genetic Medicines Conference - Director elections and auditor ratification approved; no questions raised by stockholders.GUTS
AGM 2026 - Q1 2026 net income turned positive on non-cash gains; cash runway into early 2027.GUTS
Q1 2026